Portal de Periódicos da CAPES

Central extracorporeal life support with left ventricular decompression for the treatment of refractory cardiogenic shock and lung failure

2014; BioMed Central; Volume: 9; Issue: 1 Linguagem: Inglês

10.1186/1749-8090-9-60

1749-8090

Alexander Weymann, Bastian Schmack, Anton Sabashnikov, Christopher T. Bowles, Philipp Raake, Rawa Arif, Markus Verch, U. Tochtermann, J. Roggenbach, Aron‐Frederik Popov, André Simon, Matthias Karck, Arjang Ruhparwar,

Cardiac Arrest and Resuscitation

The purpose of this prospective study was to evaluate the effects and functional outcome of central extracorporeal life support (ECLS) with left ventricular decompression for the treatment of refractory cardiogenic shock and lung failure.Between August 2010 and August 2013, 12 consecutive patients (2 female) with a mean age of 31.6 ± 15.1 years received central ECLS with left ventricular decompression for the treatment of refractory cardiogenic shock and lung failure. Underlying disease was acute cardiac decompensation due to dilated cardiomyopathy (n = 3, 25%), coronary artery disease with acute myocardial infarction (AMI) (n = 3, 25%), and acute myocarditis (n = 6, 50%). We routinely implemented ECLS by cannulating the ascending aorta, right atrium and inserting a left ventricular decompression cannula vent via the right superior pulmonary vein.All patients were successfully bridged to either recovery (n = 3, 25%), long-term biventricular support (n = 6, 50%) or cardiac transplantation (n = 3, 25%). Seven patients (58.3%) were discharged after a mean hospital stay of 42 ± 11.9 days. The overall survival from ECLS implantation to the end of the study was 58.3%. The cumulative ICU stay was 23.1 ± 9.6 days. The length of support was 8.0 ± 4.3 days (range 3-17 days).We strongly recommend left ventricular decompression in refractory cardiogenic shock and lung failure to avoid pulmonary edema, left heart distension and facilitate myocardial recovery.